Spanish pharma company Grifols has agreed to acquire Tiancheng (Germany) Pharmaceutical, which holds nearly 90% stake of German publicly listed healthcare company Biotest. The deal values 100% of Biotest at €1.6 billion. Grifols will acquire Tiancheng (Germany) Pharmaceutical from Hong Kong-registered Tiancheng International Investment. The consideration is made up of €773 million and a loan […]
Alexion acquisition of Portola : Alexion Pharmaceuticals has agreed to acquire Portola Pharmaceuticals, a commercial-stage biopharma company focused on life-threatening blood-related disorders, for $1.41 billion. Portola Pharmaceuticals developed Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], which is marketed as Ondexxya in Europe. The drug is the first and only approved Factor Xa inhibitor reversal agent, and […]
Haemonetics acquisition of enicor : US blood management company Haemonetics has acquired Germany-based medical technology manufacturer enicor, which manufactures the ClotPro whole blood coagulation testing system. Financial terms of the deal were not disclosed. The ClotProblood coagulation testing system is said to be an advanced viscoelastic diagnostic device that delivers more assays than other hemostasis […]
Reblozyl FDA approval : Celgene and Acceleron Pharma have bagged approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) for the treatment of anemia associated with beta thalassemia in adults who need regular red blood cell (RBC) transfusions. Reblozyl is now the first and only erythroid maturation agent to be approved by […]
Ultomiris EU approval : Alexion Pharmaceuticals has secured approval from the European Commission (EC) for its C5 complement inhibitor Ultomiris (ravulizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults. The Ultomiris EU approval is for patients with PNH with hemolysis with clinical symptoms that indicate high disease activity, and also for adult patients […]
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to include the treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine, and dacarbazine) for adult patients. This new approval is a significant milestone for both Takeda and the Hodgkin lymphoma community, as it […]
In a major advancement for hemophilia A therapy, Bayer’s recombinant factor VIII (rFVIII) replacement therapy, Jivi (BAY94-9027), has received approval from the U.S. Food and Drug Administration (FDA) for routine preventative treatment in individuals aged 12 years and older. This approval marks Jivi as the third hemophilia A treatment drug from Bayer to gain FDA […]